MedTech Resources

Company

Abbott

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

Abbott is on our public-company list (ticker ABT). Names searched as well: Abbott Vascular, Abbott Medical, Abbott Diabetes Care, St. Jude Medical. Naming a company here is not a recommendation of it or of any security.

Financing

Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.

Public

Listed

ABT

NYSE · ABBOTT LABORATORIES

Public float

$232.2B

Value of shares held by non-insiders on Jun 30, 2025

Revenue

$44.3B

Fiscal year ending Dec 31, 2025

Net income

$6.52B

Fiscal year ending Dec 31, 2025

R&D spending

$2.94B

Fiscal year ending Dec 31, 2025

Cash

$4.05B

As of Sep 30, 2026

Long-term debt

$29.5B

As of Sep 30, 2026

Shares outstanding

1731.9M

As of Sep 30, 2026

Capital raised as a public company

Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.

YearIPOStock soldLong-term debtConvertible debt
2021––$4.0M–

Private placements (Form D)

One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.

First saleTypeRaisedRound sizeInvestorsExemption and agentFiling
Mar 1, 2011Debt$100K$100K1Rule 506Agent: Goldman Sachs & Co.Commissions $200Form D ↗Mar 15, 2011
Mar 1, 2010Debt$70K$70K1Rule 506Agent: Goldman, Sachs & Co.Commissions $140Form D/A ↗Mar 12, 20101 amendment

Company details

From the company's latest Form D.

Legal name
ABBOTT LABORATORIES
Headquarters
Abbott Park, Illinois
Incorporated
Illinois over five years before filing
Entity type
Corporation
Revenue range
Over $100,000,000
Industry filed under
Pharmaceuticals
SEC filer
CIK 1800 ↗

Executives, directors and promoters

As listed on the latest Form D.

  • Carlos AlbanExecutive Officer
  • William SmithburgDirector
  • Glenn TiltonDirector
  • Edward MichaelExecutive Officer
  • Roxanne AustinDirector
  • Greg LinderExecutive Officer
  • Edward LiddyDirector
  • James MazzoExecutive Officer
  • John CapekExecutive Officer
  • John LandgrafExecutive Officer
  • Mary SzelaExecutive Officer
  • Miles WhiteExecutive Officer, Director
  • Heather MasonExecutive Officer
  • William OsbornDirector

Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.

Investors

5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.

The investor database is part of the paid tier

For Abbott we have 1 shareholder with 5% or more.

It is included for signed-in readers who have credit, along with the daily news digest. Credit is also what pays for AI device summaries.

Latest FDA decisions

The 8 newest of 282 since 2015.

Search the Clearance Tracker

Device trials

Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

Open in the Trial Radar
  • NCT04011722 · 333 participants · Start Sep 17, 2019 · Primary completion Jan 12, 2023

    Device: Portico™ NG (Navitor) Valve and FlexNav™ Delivery System; Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System · For: Symptomatic Severe Aortic Stenosis

    Sites: Los Angeles, California; Thousand Oaks, California; Washington D.C., District of Columbia · 28 sites in all

  • NCT06590467 · 2,500 participants (planned) · Start Aug 21, 2024 · Primary completion Dec 2029

    Device: Amplatzer™ Occlusion Devices; Epic™ Surgical Tissue Heart Valve devices · For: Heart Diseases; ASD - Atrial Septal Defect; VSD - Muscular Ventricular Septal Defect and 3 more

    Sites: Los Angeles, California; Washington D.C., District of Columbia; Miami, Florida · 36 sites in all

  • NCT07798726 · 565 participants (planned) · Start Oct 21, 2026 · Primary completion Dec 31, 2031

    Device: Cephea Mitral Valve System · For: Mitral Valve Disease; Mitral Annulus Calcification; Mitral Regurgitation and 6 more

    Sites: Wichita, Kansas

  • NCT07696182 · 300 participants (planned) · Start Nov 30, 2026 · Primary completion Sep 30, 2028

    Device: Transcatheter valve replacement therapy · For: Severe Native Calcific Aortic Stenosis; Symptomatic Heart Disease Due to Severe Native Calcific Aortic Stenosis

    Sites: Chermside, Australia; Clayton, Australia; Melbourne, Australia · 36 sites in all

  • NCT07586995 · 1,000 participants (planned) · Start Jul 2, 2026 · Primary completion Sep 2028

    Device: Tricuspid Transcatheter Edge-to-Edge Repair (TEER) · For: Tricuspid Regurgitation (TR)

    Sites: Phoenix, Arizona; La Jolla, California; Chicago, Illinois · 14 sites in all

  • NCT06526195 · 850 participants (planned) · Start Dec 13, 2024 · Primary completion Sep 2029

    Device: CardioMEMS HF System; HeartMate 3 Left Ventricular Assist System · For: Heart Failure; Heart Diseases; Cardiovascular Diseases and 1 more

    Sites: Phoenix, Arizona; Little Rock, Arkansas; Sacramento, California · 70 sites in all

Reports received

524,059

Received Nov 1, 2025 to Nov 19, 2026. Includes 155 of another or unstated type.

Malfunction reports

474,836

91% of reports

Injury reports

47,775

9.1% of reports

Death reports

1,293

0.2% of reports

Adverse event reports received per month

Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

Search the MAUDE Monitor
  • Malfunction
  • Injury
  • Death
  • Other
View as table
MonthMalfunctionInjuryDeathOther
Dec 234,5844,630610
Jan 245,2025,040674
Feb 244,6064,8701060
Mar 244,4564,917672
Apr 245,6015,140640
May 245,3965,2151083
Jun 244,7975,134620
Jul 245,9445,143601
Aug 246,5725,465801
Sep 245,4225,042661
Oct 245,6325,4611001
Nov 245,0754,813882
Dec 244,8205,169681
Jan 255,0874,321800
Feb 255,1164,258853
Mar 255,5614,506900
Apr 256,1654,6011111
May 255,9164,391871
Jun 256,1434,6301351
Jul 257,1974,6081052
Aug 256,2594,5521500
Sep 256,0554,081740
Oct 255,8854,1181212
Nov 255,6643,3021181
Dec 257,9214,1121250
Jan 268,3653,4481275
Feb 265,7373,5811141
Mar 2610,4953,9841062
Apr 2639,9464,3931122
May 2644,4724,4061200
Jun 2648,0274,4371230
Jul 2635,0054,2928934
Aug 26132,5943,9769885
Sep 26117,5774,1168013
Oct 2619,0333,7288112
Nov 260000

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

Showing the 8 newest of 1,086 recall records in FDA's data.

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.